Jaspreet Singh, DO
Urology · New Windsor, NYNPI 1598859217
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $195,570 of the $307,531 with a category attached, or 63.6%. Boston Scientific accounts for 65.6% of it on its own, with 59 other manufacturers making up the rest. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 856 payments — averaging $359.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$202K
- Coloplast$94K
- Medtronic$2K
- Antares Pharma, Inc.$1K
- Astellas Pharma US Inc$949
- Neotract Inc.$856
- plus $7K from 54 others
Across 8 payments — averaging $1284.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$7K
- Janssen Research & Development, LLC$4K
What the payments were for
- Consulting fees$74,28124%
- Speaking & faculty fees$195,57064%
- Travel & lodging$17,8826%
- Food & beverage$19,0236%
- Education$7750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$88,192
- AMS 700 CXR RTE KIT$66,923
- AMS$55,043
- TACTRA$13,000
- GENERAL - THERAPIES$12,849
- AdVance XP$7,378
- ALTIS$4,650
- GENERAL ERECTILE DYSFUNCTION$2,107
- ADVANCE$1,200
- INTERSTIM$729
- UroLift$449
- GENERAL KIDNEY STONE DISEASE$426
- PENILE & TESTICULAR RECONSTRUCTN$179
- PROGEL$176
- Axonics r-SNM System$138
- RYBELSUS$125
- Rigi10$120
- Barrigel$120
- Apligraf$119
- AMS 700$105
How this compares
$307,531 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 13 | $185,579 |
| OrgovyxRelugolix | 59 | $155,589 |
| NubeqaDarolutamide | 13 | $112,546 |
| MyrbetriqMirabegron | 110 | $90,065 |
| GemtesaVibegron | 92 | $83,978 |
| Abiraterone Acetate | 41 | $59,926 |
| XyostedTestosterone Enanthate | 45 | $51,448 |
| XgevaDenosumab | 12 | $38,017 |
| Solifenacin Succinate | 126 | $5,812 |
| Potassium Citrate ErPotassium Citrate | 25 | $5,768 |
| Tamsulosin Hcl | 344 | $5,420 |
| Testosterone | 14 | $4,938 |
| Silodosin | 44 | $3,929 |
| Estradiol | 42 | $2,531 |
| Desmopressin Acetate | 37 | $2,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $949 | $275,643123 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $345 | $239,567151 claims |
| BayerNubeqa | $361 | $112,54613 claims |
| Antares Pharma, Inc.Xyosted | $1,197 | $51,44845 claims |
| AmgenXgeva | $84 | $38,01712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in New Windsor
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.